170 related articles for article (PubMed ID: 11529283)
1. Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
van der Woude HJ; Aalbers R
Eur Respir J; 2001 Aug; 18(2):269-71. PubMed ID: 11529283
[TBL] [Abstract][Full Text] [Related]
2. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
3. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
4. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
[TBL] [Abstract][Full Text] [Related]
5. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
van der Woude HJ; Boorsma M; Bergqvist PB; Winter TH; Aalbers R
Pulm Pharmacol Ther; 2004; 17(2):89-95. PubMed ID: 15123230
[TBL] [Abstract][Full Text] [Related]
6. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
Jonkers RE; Bantje TA; Aalbers R
Respir Res; 2006 Dec; 7(1):141. PubMed ID: 17144916
[TBL] [Abstract][Full Text] [Related]
7. Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
van Schayck CP; Bijl-Hofland ID; Cloosterman SG; Folgering HT; van der Elshout FJ; Van Weel C
Eur Respir J; 2002 Feb; 19(2):240-5. PubMed ID: 11871364
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
Wong AG; O'Shaughnessy AD; Walker CM; Sears MR
Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628
[TBL] [Abstract][Full Text] [Related]
9. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
[TBL] [Abstract][Full Text] [Related]
11. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
Aziz I; Lipworth BJ
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
[TBL] [Abstract][Full Text] [Related]
12. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
13. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
14. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
Politiek MJ; Boorsma M; Aalbers R
Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
Nightingale JA; Rogers DF; Barnes PJ
Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Palmqvist M; Ibsen T; Mellén A; Lötvall J
Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
[TBL] [Abstract][Full Text] [Related]
17. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
18. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
Lipworth BJ; Dempsey OJ; Aziz I
Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
[TBL] [Abstract][Full Text] [Related]
19. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
Pizzichini MM; Kidney JC; Wong BJ; Morris MM; Efthimiadis A; Dolovich J; Hargreave FE
Eur Respir J; 1996 Mar; 9(3):449-55. PubMed ID: 8730003
[TBL] [Abstract][Full Text] [Related]
20. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
Richter K; Janicki S; Jörres RA; Magnussen H
Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
